Texas Instruments Incorporated leverages scale and long product cycles in analog and embedded chips, maintaining core status for dividend-focused investors. Industrial and automotive segments, ...
Edwards Lifesciences offers robust 10%+ revenue growth potential, but current valuation remains rich and could limit near-term upside. EW's TAVR business has reaccelerated from early in 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback